Safety and Efficacy of The Available Oral Anti diabetic Drugs In Treating Type II Diabetics During Ramadan Fasting In Sohag Governorate.

Ezzat, Mohamed Abdel Wahab; Eissa, Mahmoud Khalifa; Kamal, Yasser Mohamed; El Sayed, Adel

doi:10.21608/smj.2017.41240

Safety and Efficacy of The Available Oral Anti diabetic Drugs In Treating Type II Diabetics During Ramadan Fasting In Sohag Governorate.

Document Type : Original Article

Authors

¹ Department of Internal Medicine, Faculty of Medicine, Sohag University

² Department of Internal medicine , Faculty of Medicine, Sohag University.

10.21608/smj.2017.41240

Abstract

Objective: to assess safety and efficacy of the available oral anti diabetic Drugs during Ramadan 2016 in Sohag Governorate .
Methodology: This study was conducted on 90 type II Diabetic patients attending to outpatient Endocrinology clinic in Sohag University Hospital, on oral treatment classified into 5groups,as following , 20 (22.22%)patients on Metformin(Group I),30 (33.33%)patients on Sulphonylureas with or without metformin(Group II), 18 (20%) patients on Dipeptidyl peptidase-4 inhibitors with or without metformin (Group III),12 (13.33% ) patients on Thiazolidinedoines with or without metformin (Group V),10 (10%) patients on combinations of more than two drugs (Group VI), Mean age of patients is 59.93±7.87years, (61.11%)of them were females,(38.89%) of them were male patients and Mean duration of diabetes is 4.52±2.45(range 1:10).follow up of the patient was done by Wight changes, measuring blood sugar ,asses Hba1c ,and renal function also was done before and during ramadan.
Results: In this study we found a significant decrease in Hba1c after Ramadan with Group III (DPP4I) compared with other Groups also we found the number of hypoglycemic episodes of all groups about 10 (11.11%), more with Group II (SUs) about (9) patients developed hypoglycemia of whom 30, compared with other groups while lower number of hypoglycemia was found with Group III (DPP4I),about one patient developed hypoglycemia, also we found the number of non fasted days more with SUs,(range 2-10) also we found no body weight changes more with Group III (DPP4I) while body weight gain occurred with Group II (SUs) about 1-4Kgs .
In conclusion, Ramadan represents one of challenging issues for health care providaers all over the world . DPP4 inhibitors may considered favorable for use during and after Ramadan due to their lower rate of hypoglycemic events and weight neutral/loss effect during and after Ramadan .

Keywords

References

Diabetes Atlas 7^th Edition , December 2015 (IDF congress, Vancouver , Canada)
Al-Arouj M, RadhiaBouguerra, JohnBuse,SherifHafez,et al.,Recommendations for Management of DM During Ramadan Diabetes Care ( 2005 )vol. 28 no. 9 2305-231
Hassanein M, AbdallahK ,Schweizer et al ,A.A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc. Health. Risk.Manag.28(10), 319-326(2014), Pages 1446–1450
Al Sirifi et al, .Randomized, open- label Patients treated with SU +/- Met. Were given Sita+/- Met.
Aravind et al., Randomized, open- label Patients treated with SU +/- Met. Were given Sita+/- Met.
Al-Arouj et al. Nonrandomized, Observational , open-label study Patients prescribed Vilda/SU +/- Met. Before study start, treatment continued during the study,p344,378.
Halimi et al,.Non-randomized, Observational, open-label study. Patients prescribed Vilda + Met. /IS* + Met. Before study start, treatment continued during the study,p112,145.
Shete et al. Nonrandomized, Observational, open-label study. Patients prescribed Vilda/SU +/- Met. Before study start, treatment continued during the study,p21,28.
Hanif et al. Non-randomized, Observational, open-label study. Patients prescribed Vilda/Gliclazide + Met. Before study start, treatment continued during the study p555,570.
Devendra et al. Nonrandomized, Observational, non-interventional study. Patients prescribed Vilda/Gliclazide add on Met. Before treatment study,p412,420
Hassanein M1, Abdallah K2, Schweizer A3 et al. . Randomized,double-blined. Patients prescribed Vilda/Gliclazide add on Met. Before treatment study,p33,40
Mohamed Hassanein, Wasim Hanif ,Nicola Lister, et al, results of the VECTOR study, Pages 1367-1374 | Accepted 07 Apr 2011, Published online: 16 May 2011.
Aravind SR1, Al Tayeb K, Ismail SB et al, Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study, Curr Med Res Opin. 2011 Jun;27(6):1237-42. doi: 10.1185/03007995.2011.578245. Epub 2011 Apr 20.
D. Devendra, B. Gohel, V. Bravis , Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan , 12 August 2009 , DOI: 10.1111/j.1742-1241.2009.02171.x.
Salti I1, Bénard E, Detournay B et al, (EPIDIAR) stud,. Diabetes Care. 2004 Oct;27(10):2306-11.p312.
Wendy L. Bennett, MD, MPH et al , Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations, Published online 2011 Mar 14. doi: 10.7326/0003-4819-154-9-201105030- p55,60.